Get the Stockscreener App
3.0512
0.72%
0.0062
Anixa Biosciences Inc stock is traded at $3.0512, with a volume of 7,511.
It is up +0.72% in the last 24 hours and up +0.22% over the past month.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$3.045
Open:
$3.04
24h Volume:
7,511
Relative Volume:
0.10
Market Cap:
$99.27M
Revenue:
-
Net Income/Loss:
$-10.74M
P/E Ratio:
-8.7177
EPS:
-0.35
Net Cash Flow:
$-6.53M
1W Performance:
-2.02%
1M Performance:
+0.22%
6M Performance:
+12.34%
1Y Performance:
+5.75%
1-Day Range:
$3.0201
$3.1256
1-Week Range:
$3.02
$3.2595
52-Week Range:
$2.145
$5.13
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ANIX | 3.0668 | 99.27M | 0 | -10.74M | -6.53M | -0.35 |
| VRTX | 447.58 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Anixa Hikes on Tests - Baystreet.ca
Anixa Biosciences Advances Ovarian Cancer CAR-T Trial with 10x Dose Increase | ANIX Stock News - StockTitan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Decrease in Short Interest - MarketBeat
Anixa Biosciences Inc. (ANIX) Quarterly 10-Q Report - Quartzy
Anixa reports progress in breast cancer vaccine trial - Investing.com
Anixa reports progress in breast cancer vaccine trial By Investing.com - Investing.com Canada
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
Anixa Biosciences Reports Promising Phase 1 Vaccine Results - TipRanks
Anixa Biosciences to Present Phase 1 Breast Cancer Vaccine Trial Data at SITC Meeting | ANIX Stock News - StockTitan
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
ANIXA BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - StockTitan
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
US Penny Stocks To Consider In October 2024 - Simply Wall St
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial - Yahoo Finance
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Drops By 8.9% - MarketBeat
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - BioSpace
Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T - CGTLive™
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial By Investing.com - Investing.com South Africa
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial - Investing.com
California Biotech's Target Price 200% Higher Than Current - Streetwise Reports
ANIXAnixa Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - StockTitan
Anixa announces plans to launch Phase II breast cancer vaccine trial - Clinical Trials Arena
Anixa Shares Rise on Plans for Phase 2 Study of Breast Cancer Vaccine - MarketWatch
Anixa Biosciences sets Phase 2 trial for breast cancer vaccine - Investing.com
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine - PR Newswire
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
FY2024 EPS Estimates for Anixa Biosciences, Inc. (NASDAQ:ANIX) Lifted by Analyst - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference - PR Newswire
HC Wainwright Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Why researchers hope a new vaccine will help in the fight against breast cancer - FOX 13 News Utah
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate - Simply Wall St
Anixa Biosciences (NASDAQ:ANIX) Announces Earnings Results - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium - StockTitan
Nations Financial Group Inc. IA ADV Has $50,000 Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Anixa Biosciences to Present at Biotech Showcase 2024 - GuruFocus.com
Anixa Biosciences (FRA:CY71) Earnings per Share (Diluted) : €-0.34 (TTM As of Apr. 2024) - GuruFocus.com
ANIX (Anixa Biosciences) GF Value Rank : 0 (As of Aug. 16, 2024) - GuruFocus.com
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Grows By 33.0% - MarketBeat
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update - Defense World
Virtu Financial LLC Has $50,000 Stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by EF Hutton Acquisition Co. I - MarketBeat
Anixa Biosciences (NASDAQ:ANIX) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I - Defense World
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Purchases 21,646 Shares of Stock - Defense World
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
| Titterton Lewis H jr | Director |
Jul 31 '24 |
Buy |
3.23 |
5,580 |
18,023 |
896,334 |
| Titterton Lewis H jr | Director |
Jul 26 '24 |
Buy |
3.03 |
7,700 |
23,331 |
869,108 |
| Titterton Lewis H jr | Director |
Jul 25 '24 |
Buy |
2.81 |
796 |
2,237 |
861,408 |
| Baskies Arnold M | Director |
Jul 26 '24 |
Buy |
3.09 |
5,000 |
15,450 |
115,000 |
| Titterton Lewis H jr | Director |
Jun 14 '24 |
Buy |
2.68 |
4,000 |
10,720 |
860,612 |
| Titterton Lewis H jr | Director |
Jun 13 '24 |
Buy |
2.70 |
405 |
1,094 |
856,612 |
| Titterton Lewis H jr | Director |
Jun 11 '24 |
Buy |
2.66 |
7,102 |
18,891 |
856,207 |
| Titterton Lewis H jr | Director |
Jun 10 '24 |
Buy |
2.60 |
330 |
858 |
849,105 |
| Titterton Lewis H jr | Director |
Jun 07 '24 |
Buy |
2.52 |
10,738 |
27,060 |
848,775 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):